DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.
Erika Mohr-HollandJohnny DanielsBusisiwe BekoPetros IsaakidisVivian CoxSarah Jane SteeleOdelia MullerLeigh SnymanVirginia De AzevedoAmir ShroufiLaura Trivino DuranJennifer HughesPublished in: PloS one (2017)
The introduction of SAT during the continuation phase of RR-TB treatment does not adversely affect final RR-TB treatment outcomes in a high TB and HIV-burden setting. This differentiated, patient-centred model of care could be considered in RR-TB programmes to decrease the burden of DOT on patients and health facilities.
Keyphrases
- mycobacterium tuberculosis
- antiretroviral therapy
- hiv positive
- hiv infected
- healthcare
- human immunodeficiency virus
- hiv aids
- end stage renal disease
- hiv testing
- pulmonary tuberculosis
- hepatitis c virus
- risk factors
- newly diagnosed
- ejection fraction
- men who have sex with men
- public health
- chronic kidney disease
- peritoneal dialysis
- palliative care
- mental health
- double blind
- case report
- clinical trial
- emergency department
- patient reported outcomes
- patient reported
- chronic pain
- combination therapy
- social media
- affordable care act